Levetiracetam Ibigen

Levetiracetam, the active ingredient in Levetiracetam Ibigen, is an anticonvulsant presented as an intravenous solution for intravenous use. It treats partial‑onset, generalized tonic‑clonic and myoclonic seizures in patients requiring parenteral therapy. The product is manufactured under EU GMP standards and is indicated for patients who cannot take oral medication or need rapid seizure control.

GNH USA supplies Levetiracetam Ibigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on reliable cold‑chain logistics and regulatory documentation for cross‑border distribution.

Levetiracetam is an antiepileptic medication that modulates neuronal excitability to control seizure activity. - Partial‑onset seizures: reduces frequency and severity of focal seizures. - Generalized tonic‑clonic seizures: helps achieve seizure freedom in patients with bilateral convulsive episodes. - Myoclonic seizures: diminishes rapid, shock‑like jerks associated with juvenile myoclonic epilepsy.

Levetiracetam may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness: sensation of lightheadedness or imbalance. - Fatigue: feeling unusually tired or weak. - Headache: mild to moderate cranial pain. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or anaphylaxis. - Mood changes: depression, suicidal thoughts, or severe anxiety. - Hematologic abnormalities: low blood cell counts or platelet disorders. - Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement.

When prescribing Levetiracetam, clinicians should consider several precautionary measures to ensure patient safety. - Renal impairment: adjust dose in patients with reduced kidney function. - Hepatic dysfunction: monitor liver enzymes before and during therapy. - Psychiatric history: observe for new or worsening mood disorders. - Concomitant CNS depressants: use caution as additive sedation may occur. - Pregnancy and lactation: evaluate risk‑benefit as safety data are limited. - Store at ambient temperature: keep in original container, protect from moisture and light.

Levetiracetam can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels. - Phenobarbital: can lower drug concentration, decreasing seizure control. - Rifampicin: induces metabolism, potentially diminishing effectiveness.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase levetiracetam levels, requiring observation. - Opioids: additive CNS depression may enhance sedation. - Oral contraceptives: levetiracetam may reduce hormonal efficacy, consider alternative contraception.